2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Surgical, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

6175 Remote therapeutic monitoring during bispecific antibody step-up dosing in community practice: Feasibility and care delivery in a single-cohort study

Ben A Derman, MD, James Essell, MD2, Mustafa Steven Ascha, PhD, MS3, Michael Kolodziej, MD4, Geoffrey Calkins5, Joshua Neiman, MBA6, Lavi Kwiatkowsky7, Nathan Shumway, DO8, Ethan Basch, MD9
1 University of Chicago, Chicago, Illinois, United States
2 Cincinnati Cancer Advisors, Cincinnati, Ohio, United States
3 Canopy Care, New York City, New York, United States
4 Canopy Care, New York City, New York, United States
5 Canopy Care, New York City, New York, United States
6 Canopy Care, New York City, New York, United States
7 Canopy Care, New York City, New York, United States
8 Texas Oncology, San Antonio, Texas, United States
9 University of North Carolina, Greensboro, North Carolina, United States

Introduction: Bispecific antibodies (BsAb) for hematologic malignancies require step-up dosing to reduce the severity of acute toxicities such as cytokine release syndrome and neurotoxicity, often necessitating inpatient admission or observation. This dependence on hospital access and capacity can limit access to BsAbs in community practice. Scalable remote therapeutic monitoring (RTM) that identifies symptoms, prioritizes risk, and supports rapid escalation could help community practices develop outpatient-only step-up pathways. Canopy uses electronic patient reported outcomes, prioritized alerts, and standardized triage pathways to integrate symptom surveillance into clinical workflows. We characterized operational feasibility, detected step-up dosing, and documented clinical care among RTM users.

Methods: This single-cohort descriptive analysis used linked Canopy and electronic medical record data from four community oncology practices administering BsAb step-up doses in the outpatient setting. Patients enrolled in RTM were included if they submitted at least one symptom report during the first 28 treatment days. Report submission and clinical phone-call volume were captured along with symptoms and clinic recommendations to patients, including RTM documentation of referrals to the Emergency Department. Each practice used locally defined schedules and potentially-concerning responses generated prioritized alerts for clinical review and escalation. Tocilizumab administrations and corticosteroid orders apart from bispecific premedication were collected as well. Only events occurring on step-up at-risk days within the first 28 days following treatment initiation were included; the at-risk period extended through two days after the first full dose.

Results: 26 patients across 6 BsAbs (n=8 myeloma, n=18 for non hodgkin lymphoma) received outpatient step-up dosing. The median age was 70.5 years (interquartile range [IQR] 63.2-74.0). The median time from treatment initiation to first symptom report during step-up at-risk time was 3 days (IQR 2-5).

Patients were enrolled in RTM for 421 out of 481 (87.5%) days of the step-up period; patients submitted 170 symptom reports and were contacted via 41 clinical phone calls. The median working-hours response time to patient-reported symptoms was 5.4 [range 0.0-126.9] minutes. Among calls that used standardized symptom management pathways, most calls (9/10 [90.0%]) led to home management by triage nursing staff; the remainder sought a physician referral or evaluation. No patient was referred from home to the emergency department during step-up at-risk time within the first 28 days of treatment.

Common patient-reported symptoms included weakness/fatigue (n=13, 50.0%) and pain (n=4, 15.4%). Fever was reported by 8 patients (30.8%). Tocilizumab was administered to one patient (3.8%) on the same day as a bispecific step-up dose and to six patients (23.1%) on a day without bispecific administration during the step-up phase. Seven patients (26.9%) had a corticosteroid order not on the same day as a bispecific administration. 

Conclusions: Early Canopy RTM use was feasible at scale across several BsAbs in a real-world group of patients with hematologic malignancies undergoing step-up dosing. It allowed for prioritization and timely review and management of patient symptoms across 481 step-up patient-days, including recorded use of tocilizumab and corticosteroids for acute toxicities without the need for wearables or intensive resource use. These findings warrant further evaluation of Canopy RTM as infrastructure for outpatient-only community step-up dosing with predefined acute-care backup.

Ben A Derman, MD: Johnson and johnson - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Legend biotech usa - Consultancy (Includes expert testimony); Canopy - Consultancy (Includes expert testimony); Cellcentric - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Cota - Consultancy (Includes expert testimony); Siemens healthineers - Consultancy (Includes expert testimony); Sebia - Consultancy (Includes expert testimony)